Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.Patrizia Tosi, Michèle Cavo, Elena Zamagni et al.|PubMed|2002Cited by 111
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD.Michèle Cavo, Michele Baccarani, Norbert Pescosta et al.|Blood|2009Cited by 48
Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative AnalysisCarolina Terragna, Michèle Cavo, Elena Zamagni et al.|Blood|2010Cited by 13
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantationCarolina Terragna, Michèle Cavo, Matteo Renzulli et al.|Annals of Hematology|2013Cited by 10
Salvage Therapy With Thalidomide In Patients With Advanced Relapsed/Refractory Multiple MyelomaP. Tosi, Michèle Cavo, Elena Zamagni et al.|Journal of the Peripheral Nervous System|2002Cited by 10